Cybin Inc
(NY:
CYBN
)
0.1999
-0.0001 (-0.05%)
Official Closing Price
Updated: 8:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...
Via
Benzinga
Topics
Derivatives
Exposures
Derivatives
Cybin Touts Highlights of 'Transformative' Second-Quarter Performance
December 02, 2021
The report notes significant and swift advancements in the company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment...
Via
Benzinga
Cybin Announces FDA Approvals, Participation in Conference
December 01, 2021
Cybin (NYSE:
Via
Benzinga
Exposures
Product Safety
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
November 30, 2021
Cybin (NYSE:CYBN), a biotech company focused on progressing ...
Via
Benzinga
Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress
November 30, 2021
The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for...
Via
Benzinga
Exposures
Product Safety
Cybin Supports Psychedelic Treatment Clinic Through Grant
November 23, 2021
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first...
Via
Benzinga
Cybin Releases Q2 Financial Results
November 15, 2021
Cybin (NYSE:
Via
Benzinga
Cybin to Release Q2 2021 Results on November 15
November 09, 2021
Cybin (NYSE:
Via
Benzinga
Cybin Inc. Receives Schedule I Manufacturing License from DEA
November 04, 2021
Cybin (NYSE:
Via
Benzinga
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved
November 23, 2021
Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE:
Via
Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
Cybin 'One Step Closer' to Creating Best Therapy for Mental Health
November 19, 2021
Company releases positive results from a pre-clinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to...
Via
Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
November 15, 2021
Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited...
Via
Benzinga
Exposures
Product Safety
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
November 14, 2021
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser
November 14, 2021
This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used t...
Via
Benzinga
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'
November 11, 2021
This article was originally published on
Via
Benzinga
Cybin CEO Presenting at Jefferies London Healthcare Conference
November 11, 2021
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the...
Via
Benzinga
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
November 09, 2021
Shares plunged, despite a psilocybin-based drug reducing depression in a trial.
Via
Investor's Business Daily
32 Stocks Moving in Tuesday's Pre-Market Session
November 09, 2021
Gainers Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading. Luminar Technologies, Inc. (NASDAQ: LAZR) rose 54.2% to $26.98 in pre-market trading after...
Via
Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
November 08, 2021
Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive...
Via
Benzinga
Cybin's CYB003 Demonstrates Advantages over Oral Psilocybin for Mental Health
November 08, 2021
Cybin (NYSE:
Via
Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
Detroit Decriminalizes Psychedelics
Via
Benzinga
Exposures
Product Safety
64 Biggest Movers From Yesterday
November 09, 2021
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile...
Via
Benzinga
Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules
November 04, 2021
Cybin Inc. (NYSE:CYBN) a company developing novel psychedeli...
Via
Benzinga
Cybin Inc. Schedules R&D Briefing to Release Breakthrough Research Findings
November 02, 2021
Cybin (NEO: CYBN) (NYSE:
Via
Benzinga
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
November 01, 2021
The Week In Psychedelics:
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex
October 27, 2021
Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA)...
Via
Benzinga
Exposures
Product Safety
Cybin Inc. Announces FDA IND Authorization of Potentially Pivotal Study
October 27, 2021
Cybin (NYSE:
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.